Izrael - hebrejski - Ministry of Health

lapidot medical import and marketing ltd - acetylcysteine 0.68 g/l; acetyltyrosine 1.23 g/l - solution for infusion - solutions for parenteral nutrition - parenteral nutrition and fluid substitution prophylaxis and therapy of protein deficiency or increased protein needs.

Izrael - hebrejski - Ministry of Health

j-c health care ltd - itraconazole 100 mg - capsules - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis . onychomycosis caused by dermatophytes and/or yeasts. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.

Izrael - hebrejski - Ministry of Health

rafa laboratories ltd - itraconazole - קפסולות - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.

Izrael - hebrejski - Ministry of Health

abic ltd. - omeprazole 10.0 mg - capsules - omeprazole - - acute duodenal ulcer. - acute gastric ulcer. - helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. - reflux esophagitis:• treatment;• long-term management;• maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. - severe reflux esophagitis in children from one year of age and older • maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer.• zollinger-ellison syndrome.• treatment and prevention of nsaid – associated duodenal and gastric ulcers or erosions in high risk patients.

Izrael - hebrejski - Ministry of Health

abic ltd. - omeprazole 10.0 mg - capsules - omeprazole - - acute duodenal ulcer. - acute gastric ulcer. - helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. - reflux esophagitis:• treatment;• long-term management;• maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. - severe reflux esophagitis in children from one year of age and older • maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer.• zollinger-ellison syndrome.• treatment and prevention of nsaid – associated duodenal and gastric ulcers or erosions in high risk patients.

Izrael - hebrejski - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Izrael - hebrejski - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Izrael - hebrejski - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 10 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Izrael - hebrejski - Ministry of Health

j-c health care ltd - infliximab - אבקה להכנת תרכיז לאינפוזיה - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

Izrael - hebrejski - Ministry of Health

inovamed ltd - esomeprazole as magnesium trihydrate - esomeprazole as magnesium trihydrate 20 mg - esomeprazole